How do I choose between different sample-to-answer molecular platforms for a diagnostics R&D pilot?

Choosing between sample-to-answer molecular platforms for a diagnostics R&D pilot comes down to matching the platform to your intended use case, sample type, development burden, and future regulatory/commercial path. A good pilot should not just answer “does it detect the target?” but also “can this platform support the product I ultimately want to build?”

1) Start with the pilot objective

Be explicit about what you’re trying to learn:

• Feasibility only: Can we detect the target in the intended sample?
• Workflow fit: Can operators run it reliably with minimal training?
• Clinical performance: Sensitivity/specificity, limit of detection, interference, reproducibility
• Operational fit: Throughput, time-to-result, uptime, connectivity
• Product strategy: Is this a near-term prototype or the basis for a regulated product?

If the pilot goal is fuzzy, platform comparisons tend to become apples-to-oranges.

2) Define your “must-have” constraints first

These usually eliminate options quickly:

Sample considerations

• Sample type: swab, saliva, whole blood, plasma, urine, stool, tissue, environmental sample
• Sample volume available
• Need for lysis, extraction, purification, or enrichment
• Matrix complexity and inhibition risk
• Biosafety and contamination handling

Assay considerations

• DNA, RNA, protein, or multiplexed targets?
• Singleplex vs multiplex
• Need for quantitation vs yes/no
• Target abundance and expected prevalence
• Need to detect variants or broad panels

Operational constraints

• Turnaround time
• Batch size / random access vs walk-away automation
• Training level of intended users
• Instrument footprint
• Maintenance requirements
• Connectivity / LIMS integration
• Sample-to-answer cost

Development constraints

• Can you modify reagents, assay chemistry, or workflow?
• Is the platform open, semi-open, or locked?
• Are custom assays allowed?
• What level of vendor support is available?

3) Compare platforms on the workflow, not just the chemistry

A sample-to-answer platform is really a chain of steps:

1. Sample collection
2. Sample prep / lysis
3. Nucleic acid extraction or direct detection
4. Amplification or signal generation
5. Detection and analysis
6. Result reporting

Look for failure points in each step:

• Does the platform tolerate your real sample matrix?
• Is extraction robust enough for low-input or inhibitor-rich samples?
• Does automation reduce or just shift hands-on complexity?
• Does the software call results transparently or act as a black box?

4) Build a scoring matrix

A practical way to choose is to score platforms against weighted criteria.

Example categories:

• Analytical performance
• Sample compatibility
• Time to result
• Hands-on time
• Ease of use
• Throughput
• Scalability
• Assay flexibility
• Cost per test
• Instrument cost
• Vendor stability/support
• Regulatory readiness
• Integration with your workflow

Weight the criteria based on your product goal. For example:

• If this is for POC near-patient testing, prioritize ease of use, time-to-result, closed workflow, and robustness.
• If it’s for central lab or R&D exploration, prioritize multiplexing, assay flexibility, and data access.

5) Use real specimens early

For a pilot, don’t rely only on contrived samples unless you have to.

Test:

• Leftover clinical specimens
• Samples spanning low, medium, high analyte levels
• Negative samples with common interferents
• Edge cases: hemolysis, mucus, high protein, transport media, etc.

You want to see:

• Failure rate
• Invalid rate
• Re-run rate
• Operator variability
• Sensitivity to storage/transport conditions

6) Evaluate assay development risk

Some platforms are great for running validated assays but poor for creating new ones.

Ask:

• How much assay optimization is needed?
• Are reagents proprietary?
• Can you access raw data?
• How easy is it to troubleshoot?
• Are there known constraints on amplicon design, chemistry, or multiplexing?

If your R&D pilot is meant to generate a future product, platform flexibility matters a lot.

7) Consider regulatory and commercialization implications

Even in early R&D, the platform choice can affect the future path.

Questions:

• Is the platform likely to support CLIA, IVDR, FDA, or other regulatory strategy?
• Is the instrument manufactured under quality systems?
• Can the vendor provide documentation and change-control visibility?
• Will you be dependent on single-source consumables?
• Is there a realistic supply chain for scale-up?

A platform that is easy to pilot but impossible to commercialize can be a costly detour.

8) Run a staged pilot

A good pilot usually has 2–3 phases:

Phase 1: Technical screen

• Small number of samples
• Compare candidate platforms side-by-side
• Focus on feasibility and gross failure modes

Phase 2: Workflow and robustness

• More samples
• Multiple operators
• Multiple days
• Stress conditions and interferents

Phase 3: Pre-product assessment

• Larger specimen set
• Simulated intended use environment
• Cost, throughput, and deployment considerations

9) Common decision patterns

Choose a closed, fully integrated platform if you need:

• Rapid deployment
• Low operator skill
• Standardized workflow
• Minimal contamination risk
• Simple near-patient testing

Choose a more open platform if you need:

• Assay customization
• Multiplexing flexibility
• Access to raw data
• Faster iteration during R&D
• Lower risk of vendor lock-in

Choose a high-throughput platform if you need:

• Centralized testing
• Better cost/test at scale
• Batch processing
• Broad panel testing

10) Red flags

Be cautious if:

• The vendor cannot explain failure modes clearly
• Performance data are only from contrived samples
• Consumables are brittle or single-source without alternatives
• Assay modifications require extensive vendor intervention
• Raw data access is limited
• The platform performs well in theory but has a high invalid rate in real matrices

A simple way to decide

If you’re evaluating 3–5 platforms, ask each one:

1. Can it handle our actual sample matrix?
2. Can it meet our required sensitivity and specificity?
3. How much hands-on time and operator training does it need?
4. How flexible is it for assay development?
5. What are the costs and supply chain risks?
6. How well does it fit our regulatory/commercial strategy?

Then score them with weights aligned to your pilot goals.

If you want, I can also give you:

• a one-page platform evaluation template
• a scoring matrix spreadsheet structure
• or a vendor questionnaire for diagnostics R&D pilots.